BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Thermo Fisher Proteomics Study Uncovers Over 2,500 New Genetic-Protein Associations

Thermo Fisher’s complementary proteomic technologies uncovered more than 2,500 new biological associations: Initial findings from the PRECISE-SG100...

October 06, 2026 | News

CSL, Alentis Forge $1.55B Partnership to Advance Lixudebart for Kidney and Liver Diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared CSL and Alentis Therapeuti...

October 06, 2026 | News

FDA Expands Lilly’s Jaypirca Approval to First-Line CLL/SLL Treatment

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirto...

October 06, 2026 | News

Rznomics Secures Positive EMA Opinion for Orphan Designation of RZ-001 in Glioma

Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA...

October 02, 2026 | News

Piramal and NP2 Advance Generic Cancer Drug Cyclophosphamide Towards US Manufacturing

Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturi...

October 02, 2026 | News

CAS and Novartis Partner to Build AI-Ready Reaction Data Platform for Drug Discovery

Researchers will gain an integrated synthetic data foundation and an advanced custom search platform to support reaction data discovery and analysis ...

October 01, 2026 | News

Piramal Pharma Invests $5.3M to Expand Drug Substance Manufacturing in Canada

Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure. With its investment throug...

October 01, 2026 | Analysis

Lilly’s Retatrutide Delivers 20.8% Weight Loss in Phase III Obesity and Type 2 Diabetes Trial

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half...

October 01, 2026 | News

China Approves Jaypirca Across All Lines of Therapy for CLL/SLL

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

September 30, 2026 | News

iRegene Advances Off-the-Shelf Retinal Cell Therapy Into Clinical Trials in US and China

Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. iReg...

September 30, 2026 | News

Leo Cancer Care Advances Upright Radiation Therapy Experience for Children

Leo Cancer Care has announced plans to further invest in the treatment experience for children undergoing radiation therapy. Following the world's fi...

September 29, 2026 | News

XtalPi Files US FDA IND for AI-Designed Gut-Restricted Pan-TRK Inhibitor KQTD-126

This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's ...

September 28, 2026 | News

Nutshell Therapeutics Secures FDA IND Clearance for AI-Discovered NRF2 Degrader NTS231

Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announc...

September 28, 2026 | News

FDA Approves Mirum and Incyte’s Atebrioz for Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz...

September 28, 2026 | News

Stay Connected